MYRIAD GENETICS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) – marketscreener.com

ITEM 2.02 Results of Operations and Financial Condition.On November 2, 2021, Myriad Genetics, Inc. (the "Company") announced itsfinancial results for the three months ended September 30, 2021. The earningsrelease is attached hereto as Exhibit 99.1 to this Current Report on Form 8-Kand incorporated herein by reference.

Exhibit 99.1 contains "forward-looking statements" within the meaning of thePrivate Securities Litigation Reform Act of 1995, including statements relatingto our business, goals, strategy and financial and operational outlook. These"forward-looking statements" are management's present expectations of futureevents and are subject to a number of risks and uncertainties that could causeactual results to differ materially and adversely from those described in theforward-looking statements. These risks include, but are not limited to:uncertainties associated with COVID-19, including its possible effects on theCompany's operations and the demand for its products and services; risks relatedto the Company's ability to efficiently and flexibly manage its business amiduncertainties associated with COVID-19; the risk that sales and profit marginsof the Company's existing molecular diagnostic tests may decline or that theCompany may not be able to operate its business on a profitable basis; risksrelated to the Company's ability to generate sufficient revenue from itsexisting product portfolio or in launching and commercializing new tests; risksrelated to changes in governmental or private insurers' coverage andreimbursement levels for the Company's tests or the Company's ability to obtainreimbursement for its new tests at comparable levels to its existing tests;risks related to increased competition and the development of new competingtests and services; the risk that the Company may be unable to develop orachieve commercial success for additional molecular diagnostic tests in a timelymanner, or at all; the risk that the Company may not successfully develop newmarkets for its molecular diagnostic tests, including the Company's ability tosuccessfully generate revenue outside the United States; the risk that licensesto the technology underlying the Company's molecular diagnostic tests and anyfuture tests are terminated or cannot be maintained on satisfactory terms; risksrelated to delays or other problems with operating the Company's laboratorytesting facilities; risks related to public concern over genetic testing ingeneral or the Company's tests in particular; risks related to regulatoryrequirements or enforcement in the United States and foreign countries andchanges in the structure of the healthcare system or healthcare payment systems;risks related to the Company's ability to obtain new corporate collaborations orlicenses and acquire new technologies or businesses on satisfactory terms, if atall; risks related to the Company's ability to successfully integrate and derivebenefits from any technologies or businesses that it licenses or acquires; risksrelated to the Company's projections about the potential market opportunity forthe Company's products; the risk that the Company or its licensors may be unableto protect or that third parties will infringe the proprietary technologiesunderlying the Company's tests; the risk of patent-infringement claims orchallenges to the validity of the Company's patents; risks related to changes inintellectual property laws covering the Company's molecular diagnostic tests, orpatents or enforcement, in the United States and foreign countries; risksrelated to security breaches, loss of data and other disruptions, including fromcyberattacks; risks of new, changing and competitive technologies andregulations in the United States and internationally; the risk that the Companymay be unable to comply with financial operating covenants under the Company'scredit or lending agreements; and other factors discussed under the heading"Risk Factors" contained in Item 1A of the Company's Transition Report on Form10-K filed with the Securities and Exchange Commission on March 16, 2021, aswell as any updates to those risk factors filed from time to time in theCompany's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

--------------------------------------------------------------------------------

The exhibit(s) may contain hypertext links to information on our website orother parties' websites. The information on our website and other parties'websites is not incorporated by reference into this Current Report on Form 8-Kand does not constitute a part of this Form 8-K.In accordance with General Instruction B-2 of Form 8-K, the information setforth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be "filed" forpurposes of Section 18 of the Securities Exchange Act of 1934, as amended (the"Exchange Act"), or otherwise subject to the liability of that section, andshall not be incorporated by reference into any registration statement or otherdocument filed under the Securities Act of 1933, as amended or the Exchange Act,except as shall be expressly set forth by specific reference in such filing.

--------------------------------------------------------------------------------

Edgar Online, source Glimpses

See more here:
MYRIAD GENETICS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - marketscreener.com